Welcome to the Starpharma investor centre.Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform. |
 |
Latest News & Announcements
Starpharma receives $7.7M R&D tax incentive refund (ASX Announcement)
Jan 20th, 2022
Starpharma today announced it has received a $7.7M research and development (R&D) tax incentive refund related to the company’s Australian and international R&D expenses from the 2021 financial year. The tax refund is for eligible R&D activities across Starpharma’s portfolio, including the company’s DEP® oncology products and VIRALEZE™ antiviral nasal spray.
Read More
Shareholder Newsletter December 2021
Dec 16th, 2021
The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – December 2021 is now available to view online.
Read More
VIRALEZE™ antiviral nasal spray registered in Saudi Arabia (ASX Announcement)
Dec 14th, 2021
Starpharma today announced that VIRALEZE™ antiviral nasal spray has been registered for sale in Saudi Arabia. This is the first registration for VIRALEZE™ in the Middle East and registration in Saudi Arabia is an important step for other countries in the region.
Read More
VIRALEZE™ successfully launched in Vietnam (ASX Announcement)
Dec 13th, 2021
Starpharma today announced that since signing the commercial arrangement for VIRALEZE™ antiviral nasal spray in Vietnam, the company has received orders in excess of A$2 million, since late October. Some orders have already been delivered with further product expected to be delivered in the New Year. VIRALEZE™ successfully launched in Vietnam last week, with the formal launch events attended by clinicians, healthcare professionals, politicians, and media representatives from over 30 news channels.
Read MoreReports & Presentations
Click here for financial reports archive
AGM Chairman’s address and CEO’s presentation (ASX Announcement)
Nov 30th, 2021
Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.
Read More
Starpharma to present at Bell Potter Healthcare Conference (ASX Announcement)
Nov 9th, 2021
Starpharma has been invited to present today at the exclusive virtual 2021 Bell Potter Healthcare Conference. The Bell Potter Healthcare Conference showcases leading companies within the Australian healthcare sector and brings together industry leaders with Bell Potter’s network of international and domestic investors, analysts and advisers. The event is available to live-stream via Bell Potter Client Access on 9 – 11 November.
Read More
Quarterly Cashflow and Activities Report (ASX Announcement)
Oct 29th, 2021
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2021.
Read More
Starpharma annual report and full year financial results (ASX Announcement)
Aug 26th, 2021
Starpharma today released its annual report and financial results for the year ended 30 June 2021.
Read More
Starpharma to present at Virtual Life Sciences Investor Forum (ASX Announcement)
Jun 24th, 2021
Starpharma today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Forum. The Life Sciences Investor Forum is a leading investor conference that is attended by tens of thousands of investors, primarily US-based retail investors, as well as advisors.
Read More